Syenex is a synthetic biology technology company applying next-gen DNA synthesis, sequencing, and machine guided modeling to engineer novel genetic elements for cell and gene therapy drug developers. Our goal is to make it easier for cell engineers and drug developers to create new transformative medicines for patients in need.

Launched in 2022 with IP from Josh Leonard's lab at Northwestern, Syenex has teams in Chicago, IL and Boston, MA and is backed by three top-tier, long-term, institutional venture investors: AlleyCorp, IA Ventures, and KdT Ventures.

We offer a technology-driven environment with access to the nexus of synthetic biology and cell & gene therapy as well as a culture of courageous innovation, trust, inclusive collaboration, and empowerment.